Literature DB >> 33433899

The "Traditional Chinese medicine regulating liver regeneration" treatment plan for reducing mortality of patients with hepatitis B-related liver failure based on real-world clinical data.

Ling Dai1,2,3,4, Xiang Gao1,2,3,4, Zhihua Ye1,2,3,4, Hanmin Li5,6,7,8, Xin Yao1,2,3,4, Dingbo Lu1,2,3,4, Na Wu1,2,3,4.   

Abstract

On the basis of real-world clinical data, the study aimed to explore the effect and mechanisms of the treatment plan of "traditional Chinese medicine (TCM) regulating liver regeneration." A total of 457 patients with HBV-related liver failure were retrospectively collected. The patients were divided into three groups: the modern medicine control group (MMC group), patients treated with routine medical treatment; the control group combining traditional Chinese and Western medicine (CTW), patients treated with routine medical treatment plus the common TCM formula; and the treatment group of "TCM regulating liver regeneration" (RLR), patients treated with both routine medical treatment and the special TCM formula of RLR. After 8 weeks of treatment, the mortality of patients in the RLR group (12.31%) was significantly lower than those in the MMC (50%) and CTW (29.11%) groups. Total bilirubin level significantly decreased and albumin increased in the RLR group when compared with the MMC and CTW groups (P < 0.05). In addition, there were significant differences in the expression of several cytokines related to liver regeneration in the RLR group compared with the MMC group. RLR treatment can decrease jaundice, improve liver function, and significantly reduce the mortality in patients with HBV-related liver failure. The mechanism may be related to the role of RLR treatment in influencing cytokines related to liver regeneration.

Entities:  

Keywords:  cytokines; hepatitis B virus-related liver failure; liver regeneration; liver regeneration microenvironment; traditional Chinese medicine

Year:  2021        PMID: 33433899      PMCID: PMC7801774          DOI: 10.1007/s11684-020-0790-9

Source DB:  PubMed          Journal:  Front Med        ISSN: 2095-0217            Impact factor:   4.592


  24 in total

1.  Effects of Zuogui Wan on neurocyte apoptosis and down-regulation of TGF-beta1 expression in nuclei of arcuate hypothalamus of monosodium glutamate -liver regeneration rats.

Authors:  Han-Min Li; Xiang Gao; Mu-Lan Yang; Jia-Jun Mei; Liu-Tong Zhang; Xing-Fan Qiu
Journal:  World J Gastroenterol       Date:  2004-10-01       Impact factor: 5.742

2.  Corticosteroid and nucleoside analogue for hepatitis B virus-related acute liver failure.

Authors:  Keiichi Fujiwara; Shin Yasui; Osamu Yokosuka
Journal:  World J Gastroenterol       Date:  2015-09-28       Impact factor: 5.742

3.  Clinical trial with traditional Chinese medicine intervention ''tonifying the kidney to promote liver regeneration and repair by affecting stem cells and their microenvironment'' for chronic hepatitis B-associated liver failure.

Authors:  Han-Min Li; Zhi-Hua Ye; Jun Zhang; Xiang Gao; Yan-Ming Chen; Xin Yao; Jian-Xun Gu; Lei Zhan; Yang Ji; Jian-Liang Xu; Ying-He Zeng; Fan Yang; Lin Xiao; Guo-Guang Sheng; Wei Xin; Qi Long; Qing-Jing Zhu; Zhao-Hong Shi; Lian-Guo Ruan; Jia-Yao Yang; Chang-Chun Li; Hong-Bin Wu; Sheng-Duo Chen; Xin-La Luo
Journal:  World J Gastroenterol       Date:  2014-12-28       Impact factor: 5.742

4.  Useful properties of undifferentiated mesenchymal stromal cells and adipose tissue as the source in liver-regenerative therapy studied in an animal model of severe acute fulminant hepatitis.

Authors:  Bruna Maria Manzini; Adriana da Silva Santos Duarte; Sundararaj Sankaramanivel; Aline Lisie Ramos; Paulo Latuf-Filho; Cecilia Escanhoela; Paulo Kharmandayan; Sara Teresinha Olalla Saad; Ilka Boin; Ângela Cristina Malheiros Luzo
Journal:  Cytotherapy       Date:  2015-08       Impact factor: 5.414

5.  Expression of serum sCD163 in patients with liver diseases and inflammatory disorders.

Authors:  Jing Wang; Ye Yu; Ying Yang; Shan Shan Wu; Hai Hong Zhu; Yan Ning Liu; Wei Xia Liu; Ying Hu; Wei Wu; Cai Xia Xia; Zhi Chen
Journal:  Int J Clin Exp Pathol       Date:  2015-07-01

6.  Upregulation of toll-like receptor 4 on T cells in PBMCs is associated with disease aggravation of HBV-related acute-on-chronic liver failure.

Authors:  Chun-Li Xu; You-Hua Hao; Yin-Ping Lu; Zong-Sheng Tang; Xue-Cheng Yang; Jun Wu; Xin Zheng; Bao-Ju Wang; Jia Liu; Dong-Liang Yang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2015-12-16

7.  Liver Failure Impairs the Intrahepatic Elimination of Interleukin-6, Tumor Necrosis Factor-Alpha, Hepatocyte Growth Factor, and Transforming Growth Factor-Beta.

Authors:  Dawid Porowski; Agnieszka Wirkowska; Ewa Hryniewiecka; Janusz Wyzgał; Marek Pacholczyk; Leszek Pączek
Journal:  Biomed Res Int       Date:  2015-05-21       Impact factor: 3.411

8.  Promoter methylation status and expression of PPAR-γ gene are associated with prognosis of acute-on-chronic hepatitis B liver failure.

Authors:  Ze-Hua Zhao; Yu-Chen Fan; Qi Zhao; Cheng-Yun Dou; Xiang-Fen Ji; Jing Zhao; Shuai Gao; Xin-You Li; Kai Wang
Journal:  Clin Epigenetics       Date:  2015-10-28       Impact factor: 6.551

9.  Antioxidant treatment enhances human mesenchymal stem cell anti-stress ability and therapeutic efficacy in an acute liver failure model.

Authors:  Wen Zeng; Jia Xiao; Gang Zheng; Feiyue Xing; George L Tipoe; Xiaogang Wang; Chengyi He; Zhi-Ying Chen; Yingxia Liu
Journal:  Sci Rep       Date:  2015-06-09       Impact factor: 4.379

10.  Circulating cell death biomarker: good candidates of prognostic indicator for patients with hepatitis B virus related acute-on-chronic liver failure.

Authors:  Zhujun Cao; Fengdi Li; Xiaogang Xiang; Kehui Liu; Yuhan Liu; Weiliang Tang; Lanyi Lin; Qing Guo; Shisan Bao; Qing Xie; Hui Wang
Journal:  Sci Rep       Date:  2015-09-18       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.